Peter Bela Illei, MD

Research: Immunohistochemichal and molecular charecterization of of lung cancers. Development of novel tests for accurate typing of non-small cell carcinoma of the lung as well as new prognostic and therapeutic markers. The role of antibody mediated rejection in lung transplants. Immunohistochemichal profiling of thymic epithelial neoplasms. The role of rapid tissue processing and rapid automated immunohistochemistry in large tertiary care facilities.

Recent publications:
1. Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, Goggins M, Hruban RH New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008 Feb;32(2):188-96.
2. Sheridan T, Herawi M, Epstein JI, Illei PB. The Role of P501S and PSA in the Diagnosis of Metastatic Adenocarcinoma of the Prostate. Am J Surg Pathol. 2007 Sep;31(9):1351-5.
3. Salaria SN, Illei P, Sharma R, Walter KM, Klein AP, Eshleman JR, Maitra A, Schulick R, Winter J, Ouellette MM, Goggins M, Hruban R. Palladin is Overexpressed in the Non-Neoplastic Stroma of Infiltrating Ductal Adenocarcinomas of the Pancreas, but is only Rarely Overexpressed in Neoplastic Cells. Cancer Biol Ther. 2007 Mar;6(3):324-8. Epub 2007 Mar 24
4. Shimada S, Tsuzuki T, Kuroda M, Nagasaka T, Hara K, Takahashi E, Hayakawa S, Ono K, Maeda N, Mori N, Illei PB. Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int. 2007 Feb;57(2):60-7
5. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006 Mar 15;66(6):2970-9.
6. Shia J, Qin J, Erlandson RA, King R, Illei P, Nobrega J, Yao D, Klimstra DS. Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases. Virchows Arch. 2005 Jul 14:1-7.
7. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healye JH, Gorlick R, Meyers P, and Ladanyi M. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol. 2005 Jan 20;23(3):548-58.
8. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M: Multiple lines of evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive SV40 PCR results due to presence of SV40 sequences in common laboratory plasmids. Lancet, 2004 Sep 25, 364: 1157-1166.
9. Illei PB, Rusch V, Zakowski MF, Ladanyi M: Homozygous Deletion of CDKN2A and Co-Deletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas. Clin Can Res, 2003 Jun;9(6):2108-
10. Uren A, Merchant MS, Sun CJ, Vitolo M, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, Toretsky JA: Beta-platelet-derived growth factor receptor mediates motility and growth of Ewings sarcoma cells. Oncogene, 2003 Apr 17;22(15):2334-42.
11. Illei PB, Ladanyi M, Rusch V, Zakowski M: The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003 Feb 25;99(1):51-6.
12. Illei PB, Rosai J, Klimstra DS: Expression of thyroid transcription factor-1 and other markers in sclerosing hemangioma of the lung. Arch Pathol Lab Med, 125:1335-1339, 2001.